Print Page     Close Window

News Release


Jounce Therapeutics to Present Phase 1 Data from JTX-2011 ICONIC Trial at 2017 American Society of Clinical Oncology Annual Meeting
Poster will be first presentation of clinical data with an ICOS agonist

CAMBRIDGE, Mass., May 17, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that safety and PK/PD data from its Phase 1 ICONIC Study of JTX-2011, an agonist monoclonal antibody targeting ICOS, will be presented in a poster presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2017 in Chicago. Enrollment has been completed in both the Phase 1 monotherapy and combination dose escalation cohorts, and safety, PK and PD data from those patients will be presented at the conference. In addition, a poster that illustrates Jounce’s biomarker-driven approach to patient enrichment and provides insights into the strategy employed in the Phase 2 portion of the trial will be presented.

Poster Presentations Details:

Title: Biomarker-driven indication selection in JTX-2011 ICONIC clinical trial
Presenter: Heather Anne Hirsch, associate director of bioinformatics at Jounce Therapeutics
Abstract #: 11602
Session Title: Tumor Biology
Location: Hall A
Poster board #: 302
Date and Time: Saturday, June 3, 2017; 1:45–4:45 p.m. CT

Title: Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC
Presenter: Howard A. Burris, MD, chief medical officer and president of Sarah Cannon Research Institute
Abstract #: 3033
Session Title: Developmental Therapeutics—Immunotherapy
Location: Hall A
Poster board #: 128
Date and Time: Monday, June 5, 2017; 8–11:30 a.m. CT

About the ICONIC Study
The ICONIC study (ICOS AgONist Antibody for Immunotherapy in Cancer Patients) is an open label, dose-escalation and expansion clinical study of JTX-2011 alone or in combination with a fixed dose of nivolumab in subjects with advanced solid tumors. The four-part, adaptive design includes Parts A, B, C and D. Parts A and B comprise the Phase 1 portion of the study and are designed to provide safety, PK and PD data in both the monotherapy (Part A) and combination therapy (Part B) settings. Parts C (monotherapy) and D (combination therapy) are designed to provide preliminary efficacy proof-of-concept data. For more information on the ICONIC trial, visit clinicaltrials.gov.

About JTX-2011
Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells.  Preclinical data support that JTX-2011 may have a dual mechanism of action that stimulates anti-tumor T effector cells, and also reduces the immunosuppressive T regulatory cells in the tumor microenvironment. The company is developing JTX-2011 to treat solid tumors as a single agent and in combination with other therapies.

About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 1/2 trial. For more information, please visit http://jouncetx.com/.

Forward Looking Statements
Various statements in this release concerning Jounce’s future expectations, plans and prospects, including without limitation, Jounce’s expectations regarding the timing, progress and results of preclinical studies and clinical trials for Jounce’s product candidates and any future product candidates; the timing, scope or likelihood of regulatory filings and approvals; and Jounce’s ability to identify new targets for additional product candidates, to develop future product candidates and combination therapies, and to successfully commercialize and market products may constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward looking statements, which often include words such as “anticipate,” “estimate,” “expect,” “intend,” “may,” “on track,” “plan,” “predict,” “target,” “potential” or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled “Risk Factors” in Jounce’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Jounce’s subsequent filings with the U.S. Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact:
Katie Engleman
Pure Communications, Inc.
(919) 333-7722
katie@purecommunicationsinc.com

Investor Contact:
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com

Primary Logo

Jounce Therapeutics, Inc.